1657 related articles for article (PubMed ID: 32429703)
1. SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review.
Nascimento Junior JAC; Santos AM; Quintans-Júnior LJ; Walker CIB; Borges LP; Serafini MR
Expert Opin Ther Pat; 2020 Aug; 30(8):567-579. PubMed ID: 32429703
[TBL] [Abstract][Full Text] [Related]
2. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option.
Yao TT; Qian JD; Zhu WY; Wang Y; Wang GQ
J Med Virol; 2020 Jun; 92(6):556-563. PubMed ID: 32104907
[TBL] [Abstract][Full Text] [Related]
3. Remdesivir against COVID-19 and Other Viral Diseases.
Malin JJ; Suárez I; Priesner V; Fätkenheuer G; Rybniker J
Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33055231
[TBL] [Abstract][Full Text] [Related]
4. Overview of lethal human coronaviruses.
Chen B; Tian EK; He B; Tian L; Han R; Wang S; Xiang Q; Zhang S; El Arnaout T; Cheng W
Signal Transduct Target Ther; 2020 Jun; 5(1):89. PubMed ID: 32533062
[TBL] [Abstract][Full Text] [Related]
5. [Diagnosis, treatment, control and prevention of SARS-CoV-2 and coronavirus disease 2019: back to the future].
Ye ZW; Jin DY
Sheng Wu Gong Cheng Xue Bao; 2020 Apr; 36(4):571-592. PubMed ID: 32347053
[TBL] [Abstract][Full Text] [Related]
6. Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus.
Martinez MA
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32152082
[TBL] [Abstract][Full Text] [Related]
7. Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease.
Akaji K; Konno H
Molecules; 2020 Aug; 25(17):. PubMed ID: 32867349
[TBL] [Abstract][Full Text] [Related]
8. Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis.
Li H; Chen C; Hu F; Wang J; Zhao Q; Gale RP; Liang Y
Leukemia; 2020 Jun; 34(6):1503-1511. PubMed ID: 32372026
[TBL] [Abstract][Full Text] [Related]
9. A global treatments for coronaviruses including COVID-19.
Yousefi B; Valizadeh S; Ghaffari H; Vahedi A; Karbalaei M; Eslami M
J Cell Physiol; 2020 Dec; 235(12):9133-9142. PubMed ID: 32394467
[TBL] [Abstract][Full Text] [Related]
10. Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past.
Shah VK; Firmal P; Alam A; Ganguly D; Chattopadhyay S
Front Immunol; 2020; 11():1949. PubMed ID: 32849654
[TBL] [Abstract][Full Text] [Related]
11. The Potential of Algal Biotechnology to Produce Antiviral Compounds and Biopharmaceuticals.
Rosales-Mendoza S; García-Silva I; González-Ortega O; Sandoval-Vargas JM; Malla A; Vimolmangkang S
Molecules; 2020 Sep; 25(18):. PubMed ID: 32899754
[TBL] [Abstract][Full Text] [Related]
12. Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2.
Zhang XY; Huang HJ; Zhuang DL; Nasser MI; Yang MH; Zhu P; Zhao MY
Infect Dis Poverty; 2020 Jul; 9(1):99. PubMed ID: 32690096
[TBL] [Abstract][Full Text] [Related]
13. In vitro virucidal activity of Echinaforce®, an Echinacea purpurea preparation, against coronaviruses, including common cold coronavirus 229E and SARS-CoV-2.
Signer J; Jonsdottir HR; Albrich WC; Strasser M; Züst R; Ryter S; Ackermann-Gäumann R; Lenz N; Siegrist D; Suter A; Schoop R; Engler OB
Virol J; 2020 Sep; 17(1):136. PubMed ID: 32907596
[TBL] [Abstract][Full Text] [Related]
14. Roles of flavonoids against coronavirus infection.
Russo M; Moccia S; Spagnuolo C; Tedesco I; Russo GL
Chem Biol Interact; 2020 Sep; 328():109211. PubMed ID: 32735799
[TBL] [Abstract][Full Text] [Related]
15. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures.
Wang Y; Wang Y; Chen Y; Qin Q
J Med Virol; 2020 Jun; 92(6):568-576. PubMed ID: 32134116
[TBL] [Abstract][Full Text] [Related]
16. Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks.
Wooding DJ; Bach H
Clin Microbiol Infect; 2020 Oct; 26(10):1436-1446. PubMed ID: 32791241
[TBL] [Abstract][Full Text] [Related]
17. 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice.
Rathnayake AD; Zheng J; Kim Y; Perera KD; Mackin S; Meyerholz DK; Kashipathy MM; Battaile KP; Lovell S; Perlman S; Groutas WC; Chang KO
Sci Transl Med; 2020 Aug; 12(557):. PubMed ID: 32747425
[TBL] [Abstract][Full Text] [Related]
18. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a newly emerged pathogen: an overview.
Rathore JS; Ghosh C
Pathog Dis; 2020 Aug; 78(6):. PubMed ID: 32840560
[TBL] [Abstract][Full Text] [Related]
19. Studies on viral pneumonia related to novel coronavirus SARS-CoV-2, SARS-CoV, and MERS-CoV: a literature review.
Liya G; Yuguang W; Jian L; Huaiping Y; Xue H; Jianwei H; Jiaju M; Youran L; Chen M; Yiqing J
APMIS; 2020 Jun; 128(6):423-432. PubMed ID: 32363707
[TBL] [Abstract][Full Text] [Related]
20. Broad-spectrum coronavirus antiviral drug discovery.
Totura AL; Bavari S
Expert Opin Drug Discov; 2019 Apr; 14(4):397-412. PubMed ID: 30849247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
